[
  {
    "ts": null,
    "headline": "The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association",
    "summary": "BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's disease which was co-developed by Eisai and BioArctic, has received the 9th Bioindustry Award from the Japan Bioindustry Association (JBA).",
    "url": "https://finnhub.io/api/news?id=293b97a7cae54e8e78b0c149f7e80e6f625aa2938d80e20cd9dd849e83778a39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752652380,
      "headline": "The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association",
      "id": 135962670,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's disease which was co-developed by Eisai and BioArctic, has received the 9th Bioindustry Award from the Japan Bioindustry Association (JBA).",
      "url": "https://finnhub.io/api/news?id=293b97a7cae54e8e78b0c149f7e80e6f625aa2938d80e20cd9dd849e83778a39"
    }
  }
]